Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESCIO: Neoadjuvant IO in Renal Cell Carcinoma
NCT05148546Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and relatlimab in renal cell carcinoma (RCC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic response rate at 6 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
ipilimumabrelatlimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05148546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148546.